Clinical Trials on Risk Stratification With Biomarker in Australia
Total 5 results
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingHigh-Risk Neuroblastoma | Patient With Insufficient Response ChemoimmunotherapyFrance, Germany, Israel, Spain, United Kingdom, Belgium, Norway, Sweden, Finland, Australia, Czechia, Italy, Netherlands, Slovenia, Switzerland, Denmark, Greece, Lithuania, Slovakia
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerSpain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
-
Ablynx, a Sanofi companyCompletedUnstable Angina | Non ST Segment Elevation Myocardial Infarction (NSTEMI) | Stable Angina (Associated With High Risk PCI)Poland, Belgium, Germany, Israel, Austria, Switzerland, Czechia
-
University of UlmRecruitingAcute Myeloid Leukemia (AML) | Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2)Austria, Germany